Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
June 22 Product: Bristol Myers Squibbs Krazati Indication: Colorectal cancer Bristol Myers Squibbs oncology franchise is celebrating another approval after the FDA greenlit Krazati in combination with cetuximab for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer
Key Ingredients Glutathione : A powerful antioxidant that brightens skin and reduces pigmentation, promoting a clear and luminous complexion
Porter said it is crucial for researchers to explore new ways of reducing Alzheimers disease risk, especially in people with type 2 diabetes, because these individuals already face an elevated risk of cognitive decline and dementia
Clinical parameters such as systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also extracted from EMRs
US$ 24.99
US$ 21.76
US$ 22.04
US$ 29.24
US$ 26.92
